Literature DB >> 32415719

In vitro pharmacology of fentanyl analogs at the human mu opioid receptor and their spectroscopic analysis.

Sherif H Hassanien1, Jonathon R Bassman1, Carmelita M Perrien Naccarato2, Jack J Twarozynski2, John R Traynor2,3, Donna M Iula1, Jessica P Anand2,3.   

Abstract

Opioids are widely misused and account for almost half of overdose deaths in the United States. The cost in terms of lives, health care, and lost productivity is significant and has been declared a national crisis. Fentanyl is a highly potent mu opioid receptor (MOR) agonist and plays a significant role in the current opioid epidemic; fentanyl and its analogs (fentalogs) are increasingly becoming one of the biggest dangers in the opioid crisis. The availability of fentalogs in the illicit market is thought to play a significant role in the recent increase in opioid-related deaths. Although there is both rodent homolog in vivo and in vitro data for some fentalogs, prior to this publication very little was known about the pharmacology of many of these illicit compounds at the human MOR (hMOR). Using gas chromatography-mass spectrometry, nuclear magnetic resonance spectroscopy, and in vitro assays, this study describes the spectral and pharmacological properties of 34 fentalogs. The reported spectra and chemical data will allow for easy identification of novel fentalogs in unknown or mixed samples. Taken together these data are useful for law enforcement and clinical workers as they will aid in the identification of fentalogs in unknown samples and can potentially be used to predict physiological effects after exposure.
© 2020 John Wiley & Sons, Ltd.

Entities:  

Keywords:  GC-MS; fentanyl; mu opioid receptor; opioid epidemic; pharmacology

Mesh:

Substances:

Year:  2020        PMID: 32415719      PMCID: PMC8034271          DOI: 10.1002/dta.2822

Source DB:  PubMed          Journal:  Drug Test Anal        ISSN: 1942-7603            Impact factor:   3.345


  44 in total

1.  Fentanyl receptor assay. II. Utilization of a radioreceptor assay for the analysis of fentanyl analogs in urine.

Authors:  M E Alburges; G R Hanson; J W Gibb; C O Sakashita; D E Rollins
Journal:  J Anal Toxicol       Date:  1992 Jan-Feb       Impact factor: 3.367

2.  RTI-4614-4: an analog of (+)-cis-3-methylfentanyl with a 27,000-fold binding selectivity for mu versus delta opioid binding sites.

Authors:  R B Rothman; H Xu; M Seggel; A E Jacobson; K C Rice; G A Brine; F I Carroll
Journal:  Life Sci       Date:  1991       Impact factor: 5.037

3.  Surgeon General's Report on Alcohol, Drugs, and Health.

Authors:  Vivek H Murthy
Journal:  JAMA       Date:  2017-01-10       Impact factor: 56.272

4.  Differences in the characteristics of opioid receptor binding in the rat and marmoset.

Authors:  M Yeadon; I Kitchen
Journal:  J Pharm Pharmacol       Date:  1988-10       Impact factor: 3.765

5.  Affinity profiles of morphine, codeine, dihydrocodeine and their glucuronides at opioid receptor subtypes.

Authors:  C Mignat; U Wille; A Ziegler
Journal:  Life Sci       Date:  1995       Impact factor: 5.037

6.  New Data on Opioid Use and Prescribing in the United States.

Authors:  Anne Schuchat; Debra Houry; Gery P Guy
Journal:  JAMA       Date:  2017-08-01       Impact factor: 56.272

Review 7.  Incidence, Reversal, and Prevention of Opioid-induced Respiratory Depression.

Authors:  Albert Dahan; Leon Aarts; Terry W Smith
Journal:  Anesthesiology       Date:  2010-01       Impact factor: 7.892

8.  A series of forensic toxicology and drug seizure cases involving illicit fentanyl alone and in combination with heroin, cocaine or heroin and cocaine.

Authors:  Laureen J Marinetti; Brooke J Ehlers
Journal:  J Anal Toxicol       Date:  2014-10       Impact factor: 3.367

9.  Enantiomers of diastereomeric cis-N-[1-(2-hydroxy-2-phenylethyl)- 3-methyl-4-piperidyl]-N-phenylpropanamides: synthesis, X-ray analysis, and biological activities.

Authors:  G A Brine; P A Stark; Y Liu; F I Carroll; P Singh; H Xu; R B Rothman
Journal:  J Med Chem       Date:  1995-04-28       Impact factor: 7.446

10.  Evidence from opiate binding studies that heroin acts through its metabolites.

Authors:  C E Inturrisi; M Schultz; S Shin; J G Umans; L Angel; E J Simon
Journal:  Life Sci       Date:  1983       Impact factor: 5.037

View more
  6 in total

1.  Respiratory depressant effects of fentanyl analogs are opioid receptor-mediated.

Authors:  Neil B Varshneya; Sherif H Hassanien; Melissa C Holt; David L Stevens; Nathan K Layle; Jonathon R Bassman; Donna M Iula; Patrick M Beardsley
Journal:  Biochem Pharmacol       Date:  2021-10-19       Impact factor: 6.100

Review 2.  Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017-2020: A Review.

Authors:  Amanda L A Mohr; Barry K Logan; Melissa F Fogarty; Alex J Krotulski; Donna M Papsun; Sherri L Kacinko; Marilyn A Huestis; Jeri D Ropero-Miller
Journal:  J Anal Toxicol       Date:  2022-07-14       Impact factor: 3.220

3.  Fentanyl-related substances elicit antinociception and hyperlocomotion in mice via opioid receptors.

Authors:  Neil B Varshneya; D Matthew Walentiny; Lea T Moisa; Teneille D Walker; Luli R Akinfiresoye; Patrick M Beardsley
Journal:  Pharmacol Biochem Behav       Date:  2021-07-21       Impact factor: 3.697

4.  Pharmacokinetics and pharmacodynamics of cyclopropylfentanyl in male rats.

Authors:  Marianne Skov-Skov Bergh; Inger Lise Bogen; Nancy Garibay; Michael H Baumann
Journal:  Psychopharmacology (Berl)       Date:  2021-10-06       Impact factor: 4.415

5.  Notes from the Field: Overdose Deaths Involving Para-fluorofentanyl - United States, July 2020-June 2021.

Authors:  Jessica Bitting; Julie O'Donnell; Christine L Mattson
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2022-09-30       Impact factor: 35.301

6.  Activation of the μ-opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure.

Authors:  Anna Åstrand; Svante Vikingsson; Ingrid Jakobsen; Niclas Björn; Robert Kronstrand; Henrik Gréen
Journal:  Drug Test Anal       Date:  2020-08-14       Impact factor: 3.345

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.